LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | PI103 | 0.37 | uM | LJP6 | 1 | I16 | 72 | hr | 1389 | 1431 | 5147 | 0.2780 | 0.0159 |
| MCF7 | PI103 | 0.37 | uM | LJP6 | 2 | I16 | 72 | hr | 1389 | 1651 | 5447 | 0.3031 | 0.0916 |
| MCF7 | PI103 | 0.37 | uM | LJP6 | 3 | I16 | 72 | hr | 1389 | 1882 | 5740 | 0.3279 | 0.1599 |
| MCF7 | PI103 | 1.11 | uM | LJP6 | 1 | I15 | 72 | hr | 1389 | 1241 | 5147 | 0.2411 | -0.0579 |
| MCF7 | PI103 | 1.11 | uM | LJP6 | 2 | I15 | 72 | hr | 1389 | 1354 | 5447 | 0.2485 | -0.0129 |
| MCF7 | PI103 | 1.11 | uM | LJP6 | 3 | I15 | 72 | hr | 1389 | 1321 | 5740 | 0.2301 | -0.0242 |
| MCF7 | PI103 | 3.33 | uM | LJP6 | 1 | I14 | 72 | hr | 1389 | 1209 | 5147 | 0.2349 | -0.0708 |
| MCF7 | PI103 | 3.33 | uM | LJP6 | 2 | I14 | 72 | hr | 1389 | 1297 | 5447 | 0.2381 | -0.0342 |
| MCF7 | PI103 | 3.33 | uM | LJP6 | 3 | I14 | 72 | hr | 1389 | 1341 | 5740 | 0.2336 | -0.0171 |
| MCF7 | PI103 | 10 | uM | LJP6 | 1 | I13 | 72 | hr | 1389 | 1060 | 5147 | 0.2059 | -0.1333 |
| MCF7 | PI103 | 10 | uM | LJP6 | 2 | I13 | 72 | hr | 1389 | 1159 | 5447 | 0.2127 | -0.0877 |
| MCF7 | PI103 | 10 | uM | LJP6 | 3 | I13 | 72 | hr | 1389 | 1173 | 5740 | 0.2043 | -0.0793 |
| MCF7 | Dovitinib | 0.04 | uM | LJP5 | 1 | E24 | 72 | hr | 1389 | 4807 | 5772 | 0.8327 | 0.8296 |
| MCF7 | Dovitinib | 0.04 | uM | LJP5 | 3 | E24 | 72 | hr | 1389 | 5334 | 6038 | 0.8833 | 0.8863 |
| MCF7 | Dovitinib | 0.12 | uM | LJP5 | 1 | E23 | 72 | hr | 1389 | 4992 | 5772 | 0.8648 | 0.8635 |
| MCF7 | Dovitinib | 0.12 | uM | LJP5 | 3 | E23 | 72 | hr | 1389 | 5624 | 6038 | 0.9314 | 0.9340 |
| MCF7 | Dovitinib | 0.37 | uM | LJP5 | 1 | E22 | 72 | hr | 1389 | 4661 | 5772 | 0.8075 | 0.8023 |
| MCF7 | Dovitinib | 0.37 | uM | LJP5 | 3 | E22 | 72 | hr | 1389 | 5120 | 6038 | 0.8479 | 0.8503 |
| MCF7 | Dovitinib | 1.11 | uM | LJP5 | 1 | E21 | 72 | hr | 1389 | 4227 | 5772 | 0.7323 | 0.7186 |
| MCF7 | Dovitinib | 1.11 | uM | LJP5 | 3 | E21 | 72 | hr | 1389 | 4417 | 6038 | 0.7315 | 0.7257 |
| MCF7 | Dovitinib | 3.33 | uM | LJP5 | 1 | E20 | 72 | hr | 1389 | 3359 | 5772 | 0.5819 | 0.5368 |
| MCF7 | Dovitinib | 3.33 | uM | LJP5 | 3 | E20 | 72 | hr | 1389 | 3551 | 6038 | 0.5881 | 0.5569 |
| MCF7 | Dovitinib | 10 | uM | LJP5 | 1 | E19 | 72 | hr | 1389 | 2352 | 5772 | 0.4075 | 0.2921 |
| MCF7 | Dovitinib | 10 | uM | LJP5 | 3 | E19 | 72 | hr | 1389 | 2794 | 6038 | 0.4627 | 0.3905 |
| MCF7 | GSK 690693 | 0.04 | uM | LJP5 | 1 | F24 | 72 | hr | 1389 | 3954 | 5772 | 0.6850 | 0.6637 |